INmune Bio Inc.

INmune Bio Inc. reports financial results for Q3 2024, including a net loss of $12.1 million. Highlights include completion of enrollment for Phase 2 Alzheimer’s Disease trial, interim analysis showing EMACC's exceptional performance, and INKmune™ demonstrating safety and increased NK-Cell activity in a Phase I/II trial for metastatic Castration-Resistant Prostate Cancer.

INmune Bio, Inc. hosts a webinar on Nov 7, 2024, discussing EMACC's role in measuring cognitive change in early Alzheimer’s trials. The webinar features Dr. Judith Jaeger and CJ Barnum, and builds on a poster presentation at CTAD2024. EMACC, validated in a phase II trial, aims to improve AD clinical development by objectively capturing cognitive changes.

INmune Bio announces XPro™ promotes remyelination in demyelinating disease models, converting microglia from damaging to reparative cells by blocking soluble TNF, with implications for treating Alzheimer's Disease and other CNS diseases. Top-line cognitive results from Phase II Early AD patients trial expected in H1 2025.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.

INmune Bio Inc. (NASDAQ: INMB) will participate in the 2024 Maxim Healthcare Virtual Summit on Oct 15-17, featuring a fireside chat and virtual meetings. The company focuses on developing treatments targeting the innate immune system, including DN-TNF for Alzheimer’s and INKmune™ for cancer.

INmune Bio Inc. closed enrollment for its Phase 2 AD02 trial targeting neuroinflammation in Early Alzheimer’s Disease, exceeding the 201-patient goal. The trial uses XPro™, a TNF inhibitor, and includes biomarkers like elevated CRP, HgbA1c, ESR, or ApoE4 allele. XPro™ aims to reduce neurodegeneration and improve synaptic function.

INmune Bio's AD02 Phase II Alzheimer's trial shows exceptional EMACC performance, significant correlation with CDR-SB, and accurate disease stage differentiation. Stock up 2.32%.

INmune Bio Inc. announced exceptional performance of EMACC in AD02 Phase II Alzheimer's trial, showing significant correlation with CDR-SB. EMACC, designed for objective cognitive change measurement, demonstrated high precision and differentiation capability between disease stages.